Fig. 4: GCase activity is negatively regulated by LRRK2 kinase activity in patient-derived fibroblasts. | Nature Communications

Fig. 4: GCase activity is negatively regulated by LRRK2 kinase activity in patient-derived fibroblasts.

From: LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson’s disease patients

Fig. 4

Comparison of live-cell lysosomal GCase activity in fibroblasts derived from healthy control individuals, as well as patients with LRRK2 G2019S a and GBA1 N370S b mutations. GCase activity in patient-derived fibroblasts with LRRK2 G2019S mutations treated with either the LRRK2 inhibitors MLi-2 (600 nM) or LRRK2-IN-1 (2 µM) c–e. GCase activity measured in additional cultures derived from healthy controls f–h and from individuals with GBA1 N370S mutations i, j treated with either MLi-2 or LRRK2-IN-1. The data are presented as the mean ± SEM, n = 3 (n = 2 for N370S-2); *p < 0.05, **p < 0.01, ***p < 0.001 relative to healthy controls a, b or untreated c–j, with one-way ANOVA followed by Tukey’s multiple comparison post hoc test. Source data are provided as a Source Data file.

Back to article page